NCL-forskning
- 2024 11 Theranexus_BBDF_PR_update_Batten_V_ENG.pdf
- 2024 11 Insight of autonomic dysfunction in CLN3 disease: a study on episodes resembling paroxysmal sympathetic hyperactivity (PSH).pdf
- 2024 11 Conference Notes Malmø 14.-15.nov.pdf
- 2024 10 Six induced pluripotent stem cell lines from fibroblasts of individuals with CLN3-related conditions.pdf
- 2024 09 Project Butterfly Treatment Statement.pdf
- 2024 07 Towards_Understanding_Behaviour_and_Emotions_of_Ch.pdf
- 2024 06 Theranexus and BBDF confirm positive 18-month results for Batten-1.pdf
- 2024 04 Theranexus announces positive data on efficacy and safety in the Phase I/II trial of Batten-1.pdf
- 2024 04 Amicus Nita Patel CLN3 Manuscript Impact on family.pdf
- 2024 04 Amicus Gene Therapy in Rare Diseases.pdf
- 2024 04 Amicus Gene Therapy - Preclinical.pdf
- 2024 04 Amicus Gene Therapy - Manufacturing.pdf
- 2024 04 Amicus CLN3 Infographic.pdf
- 2023 09 Sortilin inhibition treats multiple neurodegenerative lysosomal storage disorders.pdf
- 2023 09 Program 18th International Congress on Neuronal Ceroid Lipofuscinosease Hamburg.pdf
- 2023 09 Highly Promising 12-month results in the Phase I:II trial of Batten-1 .pdf
- 2023 08 Researchers develop minipig model to study juvenile Batten disease.pdf
- 2023 07 New cellular roles for CLN3 protein identified in cell study.pdf
- 2023 06 Theranexus Prelimary Results Phase I-II.pdf
- 2023 06 Theranexus PR Positive Opinion_EMA_VDEF.pdf
- 2023 05 Seizures in protracted CLN3 disease start later, delaying diagnosis- Study.pdf
- 2023 05 FDA approves Phase 3 trial design to test Batten-1 for juvenile Batten.pdf
- 2023 04 New mouse model seen to better mimic survival in juvenile Batten.pdf
- 2023 03 Use of gemfibrozil shows promise in mouse model of juvenile Batten.pdf
- 2023 03 Abnormalities in eye tests may help diagnose juvenile Batten: Study.pdf
- 2023 01 Protein, Neuron Abnormalities Implicated in Juvenile Batten Disease.pdf
- 2023 01 Batten-1 Shows Good Safety, Tolerability in CLN3 Disease Trial.pdf
- 2022 LIVET ER NÅ, NCL-foreningens informasjonshefte.pdf
- 2022 11 Theranexus_PR_NCLS_Conference_NCLS_Chicago_FV.pdf
- 2022 10 GPD Fatty Molecules May Be Useful Biomarker in Juvenile Batten- Study.pdf
- 2022 09 Theranexus_PR_last_patient_VDEF.pdf
- 2022 08 Cardiac MRI ID’s Heart Involvement in Boy With Juvenile Batten- Report.pdf
- 2022 07 Sex bias and omission exists in NCL research.pdf
- 2022 07 CLN1 Enzyme Replacement Therapy Shows Promise in Animal Models.pdf
- 2022 02 Theranexus_PR_Start_recruitment_P1-2_Batten_VENG-.pdf
- 2021 Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype.pdf
- 2021 Eksperimentell behandling ved NCL - presentasjon fra Frambu-webinar.pdf
- 2021 Amicus med positive foreløpige data fra klinisk genterapistudie CLN3 - Pressemelding.pdf
- 2021 Amicus med positive foreløpige data fra klinisk genterapistudie CLN3 - Poster.pdf
- 2021 09 THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION (BBDF) WIN US INVESTIGATIONAL NEW DRUG (IND) APPROVAL TO START CLINICAL DEVELOPMENT OF BBDF 101.pdf
- 2021 08 NIH Study- Cost of Treating Rare Diseases ‘Large’ Relative to Other Ills.pdf
- 2021 06 Cancer Therapy Tamoxifen May Hold Promise for 2 Batten Types.pdf
- 2020 What lies ahead for NCL research.pdf
- 2020 New Approach to Correct CLN3 Mutation.pdf
- 2019 12 Avtale undertegnet mellom Theranexus og BBDF.pdf
- 2019 11 Norsk forskningprosjekt på CLN3.pdf
- 2019 09 The CLN3 gene and protein - What we know.pdf
- 2019 05 Abeona starter genterapibehandling av CLN1.pdf
- 2019 03 Therapeutic landscape for Batten disease.pdf
- 2019 03 Current and Emerging Treatment Strategies for NCL.pdf
- 2018 Oppstart av forsøk med genterapibehandling av JNCL.pdf
- 2018 Amicus Establishes Gene Therapy Pipeline - presentasjon.pdf
- 2018 Amicus Acquires Gene Therapy Portfolio - pressemelding.pdf
- 2017 FDA approves first treatment for CLN2.pdf
- 2017 European Commission approves first treatment for CLN2.pdf
- 2016 Program og abstracts NCL-konferanse Boston.pdf
- 2016 Moving towards effective therapeutic strategies for NCL.pdf
- 2016 Forskningen bak Abeonas forsøk med genterapi på CLN3.pdf
- 2014 Abstracts NCL-konferanse Cordoba.pdf
- 2012 Program og abstracts NCL-konferanse London.pdf